Researchers from UTMB have found that small molecules can represent a new class of anticancer drugs with a novel target for the treatment of lung cancer. "These compounds hold potential as an entirely new class of anticancer drugs with a unique therapeutic target for the treatment of cancers," said Dr. Jia Zhou, lead UTMB author and associate professor at Department of Pharmacology and Center for Addiction Research. "They induce high levels of cell death in lung cancer cells without triggering cell death in noncancerous cells." These findings are detailed in Nature Communications.